AQUA^® Technology Combined with ER/PR, HER2 and Ki-67...
A Valuable Recurrence Risk Assessment for Breast Cancer Patients.

IHC4 by AQUA Technology is a validated recurrence risk signature that utilizes the protein expression of ER/PR, HER2, and Ki-67 to provide precise results for you and your patients.¹ All testing is performed at Genoptix in a centralized laboratory for reproducible and accurate results.

AQUA Technology in Combination with IHC4: Accuracy and Precision for Greater Confidence

IHC4 by AQUA Technology combines the benefits of immunofluorescence and automated image analysis, providing an accurate quantitative score for protein expression that helps to:

• Minimize false-negative results²
• Provide more reproducible results than routine IHC testing²
• Broaden the dynamic range, thereby enhancing detection³
• Measure staining intensity of tumor cells by isolating epithelial cells of interest

Improved IHC4 Recurrence Risk Score with AQUA Technology.¹

Demonstrated Prognostic Value in Recurrence Risk Assessment⁴
(Cuzick et al., Journal of Clinical Oncology, Oct. 2011)

The prognostic value of the standard IHC4 score is similar to the 21-gene recurrence score in early stage, ER+ breast cancer.

• 1,125 patients: compared the Oncotype DX^® recurrence score to an IHC4 prognostic model, which used ER, PR, HER2 &
  Ki-67 status by standard IHC testing
• All four IHC markers provided independent prognostic information

For more information, call us at 800.755.1605.

1. Bartlett, J. Accepted Oral Discussion/Poster, ‘TEAM’ Study. Presented at the 2012 Annual Meeting of the American Society of Clinical Oncology. June 1-5, 2012; Chicago, IL. Abstract #517.
2. Welsh AW, Moeder CB, Kumar S, et al. Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J Clin Oncol. 2011;29(22):2978-2984.
3. Allred DC, Carlson RW, Berry DA, et al. NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. J Natl Compr Canc Netw. 2009;7 Suppl 6:S1-S21.
4. Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 2011;29(32):4273-4278.